Biotech Values

[DewDiligence]

RGDO officially becomes TBRA following 1:9 reverse split and additional financing:

http://finance.yahoo.com/news/tobira-therapeutics-completes-financing-merger-203000094.html

Tobira Therapeutics, Inc…announced today the completion of its merger with Regado Biosciences, Inc. In conjunction with the closing of the merger, Tobira raised $40 million of common stock from a combination of new investors and all current Tobira institutional investors, including the previously announced $13 million in debt that converted to common stock in this closing.

…Together with approximately $33 million net cash on Regado's balance sheet, the combined company has approximately $70 million in cash to advance clinical development of first-in-class dual CCR2/CCR5 inhibitor cenicriviroc (CVC), which is being evaluated in the Phase 2b CENTAUR clinical trial for the treatment of patients with non-alcoholic steatohepatitis (NASH) and liver fibrosis.

In connection with the merger, Regado changed its name to Tobira Therapeutics, Inc. and effected a nine for one reverse stock split. The combined company will commence trading as of tomorrow, May 5, 2015 on The NASDAQ Global Market under the symbol "TBRA."